CRISPR therapy for rare blood disease delivers “life-changing” results
Data from the United States’ first CRISPR clinical trial indicates the treatment is safe and effective two years after initial dosing. Targeting a pair of rare blood diseases, the therapy has so far been 100 percent effective in all 22 patients treated. Source of Article